You are here
AdvaMed Applauds CMS Move Toward CGM Medicare Coverage
WASHINGTON, D.C. – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement today regarding CMS’s ruling that certain continuous glucose monitors (CGMs) approved by FDA for making diabetes treatment decisions are considered durable medical equipment and are eligible to be covered by Medicare:
“AdvaMed applauds CMS’s decision to recognize certain continuous glucose monitoring devices approved for use in making diabetes treatment decisions as durable medical equipment. This significant step will allow Medicare to cover these particular life-changing devices for people with diabetes. With this decision, CMS has opened the door for millions of beneficiaries to better manage their condition and experience improved quality of life.
“CGM devices are already covered by nearly all private health plans, and CMS’s ruling follows years of advocacy efforts by AdvaMed and allied organizations to improve patient access to these advanced technologies. CGMs improve diabetes management and patients’ lives by helping to manage insulin therapy.
“CMS’s decision to cover certain therapeutic CGMs will ensure that America’s seniors will have access to a CGM technology that can simplify and improve diabetes management and overall health. However, it is important to ensure that this decision also leads to coverage for other CGM-augmented systems that use sensor readings to automatically and continuously adjust insulin delivery for patients with diabetes.”